Camp4 (CAMP) CFO Acquires 6,060 Shares in Private Placement at $1.65

Rhea-AI Filing Summary

Camp4 Therapeutics insider Kelly Gold, who serves as Chief Financial Officer, purchased 6,060 shares of Camp4 common stock at $1.65 per share in a private placement dated September 11, 2025. After the transaction, the reporting person beneficially owned 67,877 shares. The purchase was made pursuant to a Securities Purchase Agreement executed by the company, certain institutional investors, and participating directors, employees, and consultants.

This disclosure is a routine Section 16 filing showing an officer buy in a private placement rather than an open-market trade. It documents insider participation alongside institutional investors but does not provide additional financial, valuation, or company-operational context in this filing.

Positive

• Insider purchase: CFO acquired 6,060 shares, which can be interpreted as management buying equity.
• Transparent disclosure: Transaction reported on Form 4 with post-transaction ownership of 67,877 shares.
• Participation in private placement: Purchase executed under a Securities Purchase Agreement alongside institutional investors and other insiders.

Negative

• Limited context: Filing discloses the trade but provides no information on company valuation, total outstanding shares, or materiality of the purchase.
• Private placement terms not detailed: The form does not include aggregate size of the placement or whether there are lock-up or transfer restrictions.

Insights

Financial Analyst

TL;DR: Officer purchased a modest number of shares in a private placement at $1.65, increasing insider ownership to 67,877 shares.

This Form 4 reports a non-derivative acquisition by the company CFO for 6,060 shares at $1.65 per share in a private placement that included institutional investors and other insiders. Such purchases can signal management confidence but the filing alone lacks scale context versus total outstanding shares or dollar amount relative to compensation, so materiality for valuation is unclear from this form alone.

Corporate Governance Expert

TL;DR: Transaction is properly disclosed and shows insider participation in a company private placement alongside institutional investors.

The disclosure indicates the purchase was executed under a Securities Purchase Agreement involving the issuer and specified investors, which is appropriate for a private placement. The filing identifies the reporting person as an officer and provides post-transaction beneficial ownership. The form contains no indication of any exception or omission regarding the required Section 16 reporting obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Kelly

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		P		6,060	A	$1.65(1)	67,877	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kelly Gold report on the CAMP Form 4?

The report shows Kelly Gold acquired 6,060 shares of Camp4 common stock in a private placement at $1.65 per share.

How many Camp4 shares does the reporting person own after this transaction?

The reporting person beneficially owned 67,877 shares following the reported transaction.

Was this acquisition an open-market trade or a private placement?

This acquisition was made in a private placement pursuant to a Securities Purchase Agreement involving the issuer, institutional investors, and certain insiders.

What role does the reporting person have at Camp4?

The reporting person is identified as the company’s Chief Financial Officer (CFO).

Does the Form 4 show any derivative transactions by the reporting person?

No. The Form 4 lists a non-derivative acquisition of common stock and contains no derivative-security transactions.